

Management of Accidental Spinal Administration of Extended-release Epidural Morphine

J. C. Gerancher, M.D.,* Pamela C. Nagle, M.D.†

WE describe a case of accidental spinal injection of extended-release epidural morphine (EREM) intended for epidural administration. Intraoperative and postoperative management were tailored to minimize the potential for postoperative respiratory depression. The patient was successfully treated without postoperative artificial ventilation, despite known delivery of 7.5 mg EREM to her subarachnoid space.

Case Report

A 45-yr-old woman presented for exploratory laparotomy and resection of an ovarian remnant. She had a history of hypothyroidism, insomnia, and recent abdominal pain for which she took levothyroxine sodium, zolpidem tartrate, and oxycodone-acetaminophen before surgery. Her planned anesthetic was general endotracheal anesthesia, after administration of 7.5 mg lumbar EREM (DepoDur®; Pacira Pharmaceuticals, San Diego, CA) and 20 μ g subarachnoid fentanyl *via* a combined spinal-epidural technique, as per routine at our institution using lower than recommended doses of EREM as part of a combined spinal epidural technique.¹ Combined spinal-epidural was performed using a custom combined spinal-epidural tray (Smith's Medical, Keene, NH) without event, except that the resident physician accidentally exchanged the opaque 3-ml plastic syringe containing EREM for the 5-ml clear syringe designed for spinal drug administration (fig. 1). After confirming free flow of cerebrospinal fluid (CSF) and injecting the EREM into the CSF, the resident immediately removed both needle and syringe without aspirating again. The 20 μ g fentanyl intended for spinal administration was not given. A plan for intraoperative and postoperative management was developed and discussed with all anesthesia providers and the patient's surgeons. The spinal injection was made 1 h before surgery, during which time the patient was conversant and did not experience respiratory depression (fig. 2). General anesthesia was induced and maintained using no opioid, one half minimum alveolar concentration isoflurane, and 60% nitrous oxide. Dexmedetomidine was started when increases in heart rate and blood pressure were noted with incision and was maintained at 0.7 μ g \cdot kg⁻¹ \cdot h⁻¹ until extubation. Bispectral Index monitoring was maintained with a value less than 50. The patient was uneventfully extubated, in the operating room, 6 h after the spinal injection. In the postanesthesia care unit, a naloxone infusion was begun prophylactically at 40 μ g/h, a dose that we often use for mild opioid side effects. Over the next 2 h, this dose was titrated without reversal of analgesia and with improvement in somnolence to 140 μ g/h. Seven hours after spinal injection, the patient was discharged to the intermediate care unit on supple-

mental oxygen. She was somnolent but easily arousable, with a respiratory rate of 10 breaths/min and stable vital signs. Overnight, her vital signs remained stable, and no changes in naloxone infusion were required (fig. 3). The patient first reported pain 22 h after spinal injection, and the naloxone infusion was stopped. Twenty-five hours after spinal injection, intravenous morphine patient-controlled anesthesia was started, and she used 20 mg by the morning of postoperative day 2, roughly 48 h after the EREM dose. On postoperative day 1, she was also begun on 1.5 mg scopolamine diaminodiphenylsulfone every 72 h and ondansetron for nausea, which persisted until postoperative day 4. By postoperative day 2, a diagnosis of post-dural puncture headache was given consideration because the patient's persistent nausea was associated with a nonpostural headache. However, she elected to have conservative management with intravenous fluids and butalbital-acetaminophen-caffeine rather than an epidural blood patch. She was discharged on postoperative day 5 with a good understanding that a medical error had been made in her care that required heightened vigilance and extra precautions by her healthcare workers.

Discussion

This is the first published account of intrathecal administration of EREM. With no published pharmacokinetic data on the administration of intrathecal EREM, many have hypothesized that this error could lead to "profound and long-lasting respiratory depression necessitating temporary artificial ventilation, hemodynamic support, and continuous administration of opioid antagonists,"² as might also be expected in unintentional intrathecal doses of standard morphine. However, the vehicle for morphine in EREM consists of a liposomal compound known as DepoFoam® (Pacira Pharmaceuticals), which is also used in the administration of intrathecal chemotherapeutic agents to allow for the extended release of this agent in the CSF.^{3,4} For EREM, none of more than 900 patients in five randomized controlled studies of efficacy were described to experience known spinal administration of EREM,⁵⁻⁹ and there are no descriptions or published data in the literature to guide the treatment of a patient who receives intrathecal EREM.

Assuming that the morphine in EREM could behave as immediate release in CSF, management of a patient without artificial ventilation after spinal administration of 7.5 mg morphine may seem novel. However, such management after 6-25 mg spinally administered morphine has been previously described in the literature. Therapy in these patients consisted of observation without intubation, CSF aspiration, and naloxone infusion.¹⁰⁻¹³ We did not know how the EREM dose we administered would behave in comparison with these similar doses of standard morphine. We chose to institute increased monitoring during the postoperative period along with a naloxone infusion, titrated to a low dose without reversal of

* Associate Professor of Anesthesiology, Section Head of Regional Anesthesia and Acute Pain Management, † Assistant Professor of Anesthesiology.

Received from Wake Forest University School of Medicine, Winston-Salem, North Carolina. Submitted for publication October 30, 2007. Accepted for publication February 28, 2008. Support was provided solely from institutional and/or departmental sources.

Timothy J. Brennan, Ph.D., M.D., served as Handling Editor for this exchange.

Address correspondence to Dr. Gerancher: Department of Anesthesiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157-1009. jgeranch@wfbmc.edu. Information on purchasing reprints may be found at www.anesthesiology.org or on the masthead page at the beginning of this issue. ANESTHESIOLOGY's articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue.




Fig. 1. Photograph of combined spinal–epidural components showing the clear glass 5-ml syringe (left) and the opaque extended-release epidural morphine syringe (right).

analgesia. Although pharmacokinetic data after intrathecal EREM was of interest to us, we did not draw serial serum levels of morphine because it was not clinically warranted.

Although we do not have data to support whether the vehicle for EREM diminished or increased the likelihood of artificial ventilation, this case suggests that accidental administration of EREM may be successfully managed without the negative sequelae that have been previously




Fig. 2. Graphs of vital signs immediately after injection and in the postanesthesia care unit (PACU). HR = heart rate; RR = respiratory rate; SBP = systolic blood pressure; SpO₂ = pulse oximetry.

hypothesized.² In fact, we were surprised that the spinally administered EREM in this patient seemed to behave similarly to epidurally administered EREM. However, of note, our patient did seem to experience more somnolence initially, less analgesia subsequently, and a great deal more nausea than typically encountered with epidurally administered EREM.^{5–9} This may be explained by the unknown pharmacokinetics of EREM in the spinal space. However, partial dose administration may also help to explain this patient's favorable outcome. Although a dose much higher than is typical for spinal administration of morphine was most likely given, it remains possible that the entire




Fig. 3. Graph of vital signs through 48 h in intermediate care. The dotted line represents the point at which naloxone was discontinued and the dashed line represents the point at which an intravenous patient-controlled analgesic infusion was started. HR = heart rate; RR = respiratory rate; SBP = systolic blood pressure; SpO₂ = pulse oximetry.

7.5 mg EREM was not administered spinally because we did not attempt to aspirate CSF after administration of the drug.

Our current system for safe EREM administration has safeguards that failed us and this patient. We use custom-assembled combined spinal-epidural kits with uniform assignment of syringes of different type and size filled with solutions with visibly different opacity (fig. 1). Because of this sentinel event, we are introducing additional safeguards to include withdrawal of EREM from the vial only after the spinal needle has been removed from the patient, and verbal confirmation of the drug and dose being given by two providers at the time the EREM is administered.

In conclusion, our practice of using a dose of EREM lower than recommended,¹⁴ the patient's previous use of opioid and possible opioid tolerance, and her good health may have contributed to this outcome. In any case, this single example of intrathecal EREM is not presented to imply that this practice is safe: The pharmacokinetics of EREM in the spinal space have not been published, and this route of administration has not been adequately studied. Rather, we believe this case does imply that preservation of an acceptable patient recovery is possible with appropriate and thoughtful management of known accidental spinal administration of EREM.

References

1. Nagle PC, Gerancher JC: DepoDur® (extended-release epidural morphine): A review of an old drug in a new vehicle. *Tech Reg Anesth Pain Manage* 2007; 11:9-18
2. Alam M, Hartrick CT: Extended-release epidural morphine (DepoDur): An old drug with a new profile. *Pain Pract* 2005; 5:349-53
3. Angst MS, Drover DR: Pharmacology of drugs formulated with DepoFoam: A sustained release drug delivery system for parenteral administration using multivesicular liposome technology. *Clin Pharmacokinet* 2006; 45:1153-76
4. Howell SB: Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology. *Cancer J* 2001; 7:219-27
5. Gambling D, Hughes T, Martin G, Horton W, Manvelian G: A comparison of DepoDur, a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. *Anesth Analg* 2005; 100:1065-74
6. Hartrick CT, Martin G, Kantor G, Koncelik J, Manvelian G: Evaluation of a single-dose, extended-release epidural morphine formulation for pain after knee arthroplasty. *J Bone Joint Surg Am* 2006; 88:273-81
7. Viscusi ER, Martin G, Hartrick CT, Singla N, Manvelian G, EREM Study Group: Forty-eight hours of postoperative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulation. *ANESTHESIOLOGY* 2005; 102:1014-22
8. Carvalho B, Riley E, Cohen SE, Gambling D, Palmer C, Huffnagle HJ, Polley L, Muir H, Segal S, Lihou C, Manvelian G, DepoDur Study Group: Single-dose, sustained-release epidural morphine in the management of postoperative pain after elective cesarean delivery: Results of a multicenter randomized controlled study. *Anesth Analg* 2005; 100:1150-8
9. Carvalho B, Roland LM, Chu LF, Campitelli VA III, Riley ET: Single-dose, extended-release epidural morphine (DepoDur) compared to conventional epidural morphine for post-cesarean pain. *Anesth Analg* 2007; 105:176-83
10. Lacassie H, Eberhard ME, Galeno L: Morfina intratecal como analgesia en el trabajo de parto. *Rev Chil Anestesia* 1983; 12:157-60
11. Perrot G, Muller A, Laugner B: Accidental overdose of intrathecal morphine: Treatment with intravenous naloxone alone [in French]. *Ann Fr Anesth Reanim* 1983; 2:412-4
12. Sauter K, Kaufman HH, Bloomfield SM, Cline S, Banks D: Treatment of high-dose intrathecal morphine overdose: Case report. *J Neurosurg* 1994; 81:143-6
13. Cannesson M, Nargues N, Bryssine B, Debon R, Boselli E, Chassard D: Intrathecal morphine overdose during combined spinal-epidural block for caesarean delivery. *Br J Anaesth* 2002; 89:925-7
14. DepoDur [package insert]. San Diego, Pacira Pharmaceuticals, 2007

Anesthesiology 2008; 108:1149

Copyright © 2008, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

In Reply:—We read with great interest the case report by Dr. Gerancher and Dr. Nagle¹ about the effects of accidental spinal administration of extended release epidural morphine (DepoDur®; Pacira Pharmaceuticals, San Diego, CA). In their report, the authors note that no published pharmacokinetics data are available for this drug after intrathecal administration.

Pacira Pharmaceuticals, Inc., performed a study of the effects of DepoDur® on intrathecal administration to dogs during the drug's development, which we would like to report. Adult male beagle dogs ($n = 3$, each group) were prepared with chronic intrathecal and epidural catheters. Animals received 30 mg DepoDur® in 3 ml by both routes, 7 days apart, in random order. Seven days after the last of the intrathecal and epidural dosing intervals, animals received an intravenous dose of morphine sulfate, 30 mg in 3 ml. All morphine treatments resulted in mild behavioral depression in arousal, muscle tone, and coordination; no animal required intervention. The rank order of time to onset was shortest for intravenous morphine sulfate, followed by intrathecal DepoDur® and then epidural DepoDur®. Duration was less than 10 h after intravenous administration and 48-72 h after intrathecal and epidural administration. Administration of morphine by all routes evoked mild bradycardia of similar onset and magnitude. Duration was shortest after intravenous administration; duration was similar after intrathecal and epidural administration. A mild decrease in blood pressure was observed after intravenous administration, whereas intrathecal and epidural administration were without effect. Respiratory rates were moderately diminished after all routes of administration. The duration of effect was similar after all

routes. Body temperature was not affected after intravenous or epidural administration, whereas a modest decline was observed after intrathecal administration that resolved by 24 h.

Free morphine concentration after intravenous dosing declined to below detection limit by 24 h. In contrast, free morphine was detected for several days after intrathecal or epidural administration. The pharmacokinetic parameters for free morphine in the circulation were similar after intrathecal and epidural administration: T_{max} was 6.3 ± 2.0 compared with 4.0 ± 1.0 h, C_{max} was 39 ± 18 compared with 78 ± 6 ng/ml, $t_{1/2}$ was 9.7 ± 3.2 compared with 10.3 ± 3.3 h, and $AUC_{0-\infty}$ was 727 ± 84 compared with $1,002 \pm 150$ ng · h · ml⁻¹. In conclusion, after administration of DepoDur® intrathecally or epidurally to dogs, morphine release from the liposomal vehicle, as measured by serum pharmacokinetics of free morphine, was similar. No direct cerebrospinal fluid pharmacokinetics data have been collected after intrathecal administration of DepoDur®. In general, epidural and intrathecal DepoDur® resulted in prolonged and similar behavioral and physiologic effects. Pacira Pharmaceuticals never recommends intrathecal administration of DepoDur®, and the risk of respiratory depression from intrathecal injection is unknown.

Ronald M. Burch, M.D., Ph.D., Pacira Pharmaceuticals, Inc., San Diego, California. ronburch@pacira.com

Reference

1. Gerancher JC, Nagle PC: Management of accidental spinal administration of extended-release epidural morphine. *ANESTHESIOLOGY* 2008; 108:1147-9

(Accepted for publication March 3, 2008.)

Support was provided by Pacira Pharmaceuticals, Inc., San Diego, California.